Market Overview

Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) – New Rerport by Daedal Research

Share:

 

The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)” provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices.

The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Further, companies like Pfizer Inc, Merck &  Co, Allergan Inc and Alcon (Division of Novartis) are profiled in the report.

 

Country Coverage

The US
Japan

Company Coverage

Pfizer Inc,
Merck & Co,
Allergan Inc and
Alcon (Division of Novartis)

Executive Summary

Glaucoma, the second most common cause of blindness worldwide is generally characterized by relatively high intraocular pressure (IOP) as a result of impaired drainage of fluid, known as aqueous humor, from the eye. Currently approved treatments for glaucoma include a number of pharmaceutical drugs, laser therapies and surgical procedures. Glaucoma treatment forms a significant portion of the overall eye care market.

The Global Glaucoma Treatment Market has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years.

The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug.

Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed.

 

Table of Contents:

 

1. Executive Summary

2. Glaucoma: A Major Cause of Vision Loss

2.1 Overview

2.2 Types of Glaucoma

2.3 Prevention and Treatment of Glaucoma

3. Global Eye Care Market: An Analysis

3.1 Global Eye Care Market: Sizing and Growth

3.2 Global Eye Care Market Segmentation

3.3 Eye Care Surgical Market

3.4 Ophthalmic Pharmaceuticals Market

3.5 Vision Care Market

4. Global Glaucoma Treatment Market: An Analysis

4.1 Global Glaucoma Treatment Market: Sizing and Growth

4.2 Global Glaucoma Treatment Market: Share by Type of Drugs

4.3 Glaucoma Devices Market

5. Regional Analysis: Glaucoma Treatment Market

5.1 The US Glaucoma Treatment Market

5.2 Japan Glaucoma Treatment Market

6. Market Dynamics: Global Glaucoma Treatment Market

6.1 Growth Drivers: Glaucoma Treatment Market

6.1.1 Rising Ageing Population

6.1.2 Rising Healthcare Expenditures

6.1.3 New Glaucoma Drug Delivery Devices

6.2 Key Issues: Glaucoma Treatment Market

6.2.1 Strict Regulation and Marketing Approval

6.2.2 Long Product Development Process

6.2.3 Side Effects of Glaucoma Medications

6.3 Market Trends: Glaucoma Treatment Market

6.3.1 Medicare Coverage of Glaucoma Patients

6.3.2 New Laser Technologies

6.3.3 Demand for Combination Glaucoma Drugs

7. Competitive Landscape: Glaucoma Treatment Market

8. Company Profiles: Glaucoma Treatment Market

8.1 Pfizer Inc.

8.1.1 Business Description

8.1.2 Financial Overview

8.1.3 Business Strategies

8.2 Merck & Co., Inc.

8.2.1 Business Overview

8.2.2 Financial Overview

8.2.3 Business Strategies

8.3 Allergan Inc.

8.3.1 Business Description

8.3.2 Financial Overview

8.3.3 Business Strategies

8.4 Alcon (Division of Novartis)

8.4.1 Business Description

8.4.2 Financial Overview

8.4.3 Business Strategiest

 

List of Figures:

 

Figure 1: Diagram of the Structure of the Eye (left) and Damage from Glaucoma (Right)

Figure 2: Global Eye Care Market Size in US$ Billion, 2013-2018F

Figure 3: Global Eye Care Market Segmentation in %, 2013

Figure 4: Breakup of Global Eye Surgical Market in US$ Billion, 2013

Figure 5: Breakup of Global Ophthalmic Pharmaceuticals Market in US$ Billion, 2013

Figure 6: Breakup of Global Vision Care Industry in US$ Billion, 2013

Figure 7: Global Glaucoma Treatment Market Sales in US$ Billion, 2010-2013

Figure 8: Total Worldwide Glaucoma Market Annual Prescriptions in Million, 2012-2019F

Figure 9: Forecast Global Glaucoma Treatment Market in US$ Billion, 2014F-2019F

Figure 10: Market Share of Commonly Prescribed Glaucoma Drugs in %, 2013

Figure 11: Global Glaucoma Devices Market Size in US$ Million, 2008-2013

Figure 12: Global Glaucoma Devices Market Segmentation in %, 2013

Figure 13: The US Glaucoma Market Sales in US$ Billion, 2012-2020F

Figure 14: The US Glaucoma Market Annual Prescriptions in Million, 2012-2020F

Figure 15: The US Glaucoma Market Composition in %, 2013

Figure 16: The US Prostaglandin Market Sales and Annual Prescriptions, 2012-2020F

Figure 17: The US Beta Blocker Market Sales and Annual Prescriptions, 2012-2020F

Figure 18: The US Combination Glaucoma Market Sales and Annual Prescriptions, 2012-2020F

Figure 19: The US Carbonic Anhydrase Market Sales and Annual Prescriptions, 2012-2020F

Figure 20: Japan Prescription Ophthalmic Pharmaceuticals Market in US$ Billion, 2009-2013

Figure 21: Japan Prescription Ophthalmic Pharmaceuticals Market Segmentation in %, 2013

Figure 22: Japan Glaucoma Treatment Market in US$ Million, 2012-2013

Figure 23: Global Total Population ages 65 and above in Million, 2007-2013

Figure 24: Global Healthcare Expenditures Per Capita in US$, 2007-2013

Figure 25: Share of Monotherapies and Combinations Glaucoma Drugs in %, 2013 versus 2018F

Figure 26: Shares of Global Ophthalmic Laser Market Players in %, 2013

Figure 27: Pfizer’s Revenue Share by Business Segments in %, 2013

Figure 28: Pfizer – Revenues from Xalatan/Xalacom in US$ Million, 2011-2013

Figure 29: Merck & Co., Inc. Revenue by Business Segment in %, 2013

Figure 30: Merck & Co., Inc – Revenue from Cosopt/Trusopt in US$ Million, 2011-2013

Figure 31: Allergan Inc Business Segmentation by Revenue in %, 2013

Figure 32: Allergan – Revenue from Total Glaucoma Products in US$ Million, 2011-2013

Figure 33: Revenue from Alcon Division in US$ Million, 2011-2013

 

Table 1: Commonly Used Glaucoma Medications with Generic Equivalents

Table 2: The US – Xalatan (latanoprost) Estimated Glaucoma Market, 2012-2020F

Table 3: The US - Lumigan (bimatoprost) Estimated Glaucoma Market (AGN), 2012-2020F

Table 4: The US – Travatan (travoprost) Estimated Glaucoma Market, 2012-2020F

Table 5: The US – Zioptan Estimated Glaucoma Market, 2012-2020F

Table 6: The US - Combigan Estimated Glaucoma Market (AGN), 2012-2020F

Table 7: The US - Cosopt Estimated Glaucoma Market (AGN), 2012-2020F

Table 8: The US - Simbrinza Estimated Glaucoma Market (NVS/Alcon), 2013-2020F

Table 9: The US – Carbonic Anhydrase Inhibitors (Branded) Estimated Glaucoma Market, 2012-2020F

Table 10: The US – Carbonic Anhydrase Inhibitors (Generics) Estimated Glaucoma Market, 2012-2020F

Table 11: Alcon - Ophthalmic Projects/Products Planned in Coming Years

 

For further details, kindly visit :

 

http://www.daedal-research.com/global-glaucoma-treatment-market-trends-and-opportunities-2014-2019

 

Rajeev Kumar

(Business Development Manager)

Address:  36 SFS Flats

Paschim Vihar

New Delhi-110063

Mobile: +91-8743975789

Tel: +91-120-4553017

Mail ID - info@daedal-research.com

 

Daedal Research is a research and consulting firm specialized in providing research reports and customized business research and analysis. For more Information:

http://www.daedal-research.com

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

 

Related Articles

View Comments and Join the Discussion!